Author:
Merrick B. Alex,Witzmann Frank A.
Reference140 articles.
1. Chapal N, Molina L, Molina F, Laplanche M, Pau B, Petit B (2004) Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: Applications in diabetes and cancer. Fundam Clin Pharmacol 18: 413–422
2. Leighton JK (2005) Application of emerging technologies in toxicology and safety assessment: Regulatory perspectives. Int J Toxicol 24: 153–155
3. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN (2005) Pharmacogenomics and clinical biomarkers in drug discovery and development. Am J Clin Pathol 124 Suppl: S29–41
4. Siest G, Marteau JB, Maumus S, Berrahmoune H, Jeannesson E, Samara A, Batt AM, Visvikis-Siest S (2005) Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. Eur J Pharmacol 527: 1–22
5. Bandara LR, Kennedy S (2002) Toxicoproteomics-A new preclinical tool. Drug Discov Today 7: 411–418
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献